Warning: in_array() expects parameter 2 to be array, null given in /home/pharmalicensing/public_html/detail.php on line 234

Warning: in_array() expects parameter 2 to be array, null given in /home/pharmalicensing/public_html/inc_stats.php on line 82

Warning: array_push() expects parameter 1 to be array, null given in /home/pharmalicensing/public_html/inc_stats.php on line 85
Pharmalicensing | Life Science's Global Technology Marketplace
Save this technology
close
Save to Existing Project
Save to a New Project
Tumor-infiltrating Follicular Helper T Cells
Université Libre de Bruxelles Belgium flag Belgium
Abstract ID:
The invention provides an improved signature for prognostic of Breast Cancer outcome based on the organized anti-tumor immune response of patients. The so-called Immunological Grade relies on the combination of a molecular score from a 8-gene signature as...
Contact Arnaud Quintens
Participants
You
Email me a copy of this message
STATE OF THE ART

Although CD8+ cytotoxic T cells have been considered as the key component of effective anti-tumor immunity, and breast tumors with higher levels of infiltrating CD8+ T cells have been associated with better patient survival, studies have also shown that CD8+ T cells frequently fail to fully function in vivo if there is a lack of adequate CD4+ T cell help. The role played by individual CD4+T (Th) subsets in cancer immunity remains however largely controversial.

THE INVENTION

The invention provides an improved signature for prognostic of Breast Cancer outcome based on the organized anti-tumor immune response of patients. The so-called Immunological Grade relies on the combination of a molecular score from a 8-gene signature associated with follicular helper T (Tfh) cells and a morphological score based on the density of tumor infiltrating lymphocites (TIL) and the detection of organized tertiary lymphoid structures (TLS). It has been designed to reflect patients' intrinsic immune response at diagnosis and to provide thereby powerful means to predict survival as well as preoperative response to chemotherapy.

POTENTIAL APPLICATIONS

The Immunological Grade (IG) can be effectively used to stratify Breast Cancer (BC) patients for treatment, especially with respect to preoperative response to chemotherapy in the context of neo-adjuvant therapy. IG is particularly well-suited to complement the service/product portfolio of genomics service providers and pharma industries involved in the development of new BC therapies.

KEY ADVANTAGES OF THE TECHNOLOGY

- IG outperforms current immune signature

- Provides Strong Prognostic Power for HER2+ subtype

- Relies on standardized routinely available detection
GO PREMIUM TO GET PATENT INFORMATION
Type of Business Relationship Sought
License Agreement, Product Co-Development
FEATURED
Last Updated Sep 2014
Technology Type
Phase of Development
UNIVERSITY